Necrobiosis lipoidica

Published on 19/03/2015 by admin

Filed under Dermatology

Last modified 19/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 415 times

Necrobiosis lipoidica

Arif M. Aslam and Ian Coulson

Evidence Levels:  A Double-blind study  B Clinical trial ≥ 20 subjects  C Clinical trial < 20 subjects  D Series ≥ 5 subjects  E Anecdotal case reports

image

(From Pei-Shan Yen, Kuo-Hsien Wang, Wei-Yu Chen, Ya-Wen Yang, Wen-Tsao Ho, 2011. The many faces of necrobiosis lipoidica: a report of three cases with histologic variations. Dermatologica Sinica 29 (2), 67–71.)

Necrobiosis lipoidica (NL) is a chronic cutaneous granulomatous condition with degenerative connective tissue changes. The pathophysiology remains unknown but both granulomatous and angiopathic mechanisms have been proposed. It is seen in 1 in 300 diabetics but may be unassociated with glucose intolerance. NL initially appears as an atrophic plaque found over pretibial sites. Ulceration may occur after trauma, with ensuing pain. NL may rarely be complicated by squamous cell carcinoma.

Management strategy

Smoking cessation and avoiding trauma to the affected shins are key factors to avoid transformation from an unsightly plaque into a painful, recalcitrant ulcer. The progression of new lesions may be halted by intralesional or occluded potent topical corticosteroids applied to the margins of the lesions. Once atrophy has developed there is little that will reverse this, although topical retinoids may be tried. Telangiectasia is often marked and has been treated with pulsed dye laser. Extensive lesions may justify trials of nicotinamide or prednisolone. Antiplatelet therapy in the form of aspirin, dipyridamole, or ticlopidine has its enthusiasts, though responses are inconclusive. Topical psoralen and UVA (PUVA) has received recent interest and may arrest progression and improve the appearance. A variety of systemic anti-inflammatory and immunosuppressive agents have received recent attention, including mycophenolate mofetil, fumaric acid esters, cyclosporine, antimalarials, thalidomide, and pentoxifylline. Infliximab and etanercept have also been proposed.

The chronically ulcerated lesion is a challenge; antibiotics deal with secondary infection, appropriate dressings may be required, and growth factors such as becaplermin and granulocyte–macrophage colony-stimulating factor (GM-CSF) may accelerate healing. As diabetics may have coexisting large vessel atherosclerosis that may contribute to ulceration, non-invasive arterial studies or angiography need to be considered if clinically indicated. Venous hypertension may also contribute to the localization and ulceration of necrobiosis. Excision and grafting may transform the patient’s quality of life and improve cosmesis.

Work with the diabetes specialist to optimize diabetic control.

Specific investigations




First-line therapies

imageStop smoking and optimize diabetic control C
imageIntralesional or topical corticosteroids under occlusion D




Second-line therapies

Buy Membership for Dermatology Category to continue reading. Learn more here
imageSystemic corticosteroids D
imageAspirin and dipyridamole C
imageTiclopidine D
imageNicotinamide D
imageClofazimine D